secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001213900-24-029582
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX reports FY2023 net loss $26.2M; completes APT acquisition and $50M financing
--------------------------------------------------------------------------------

- FY2023 net loss $26.2M vs $28.3M prior year; R&D expenses $16.7M.
- Completed acquisition of Adaptive Phage Therapeutics (March 2024), gaining BX211 for DFO.
- Closed $50M private placement led by Deerfield and AMR Action Fund; used to fund BX004 and BX211 through key data readouts.
- Cash, restricted cash and short-term deposits $15.9M at Dec 31, 2023; company states sufficient for 12 months post-financing.
- BX211 Phase 2 DFO trial enrolled 32 of 45 patients; topline results expected Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024029582/0001213900-24-029582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024029582/ea0203239-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-029582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer